A C C E P T E D
Infective endocarditis (IE) caused by methicillin-resistant Staphylococcus 1
aureus with reduced vancomycin susceptibility (SARV) has been reported 2 worldwide. We report successful treatment of a pediatric patient with SARV IE and 3 strain characterization. The MIC of vancomycin rose from 1.5 to 2µg/mL and the 4 SARV was confirmed by population analysis. 5 vancomycin is the leading treatment of choice. The emergence of isolates with reduced 6 susceptibility to vancomycin (SARV), including hVISA and VISA, among patients with 7 endocarditis has become problematic around the world (1,6,11). The possible reason for 8 the emergence of SARV and ideal therapy for patients with endocarditis due to SARV are 9 still unknown. We report the successful treatment with a combination of linezolid and 10 fucidic acid for a patient with hospital-associated SARV endocarditis. Our 11 characterization of the causative strain in clinical sequence also provides an association 12 between failure of vancomycin therapy and the emergence of SARV. 13
A C C E P T E D
Similar to other patients with hVISA, VISA or SARV infections (3, 12, 20) vancomycin MIC of <0.5 µg/mL responded much more readily than did MRSA strains 1 with MIC of 1-2 µg/mL (17) . Subtle changes in increasing vancomycin MIC well within 2 the susceptible range and differences in susceptibility to killing may contribute to clinical 3 failure (16) . In the present case, we provide a clear clinical sequence. We suggest that a 4 healthcare-associated vancomycin-susceptible S. aureus strain with higher vancomycin 5 MIC and reduced susceptibility subpopulation was primarily responsible for the infection 6 initially but ineffective vancomycin therapy selected for the SARVs and resulted in 7 glycopeptide treatment failure. 8
Of noteworthy is that resistance to rifampin also developed during vancomycin and 9 rifampin combination therapy in our case. In a previous study, in vitro antagonism had 10 been shown when rifampin was added to vancomycin (18) . In a prospective, randomized 11 trial, Levine et al. demonstrated that the addition of rifampin to vancomycin was 12 counterproductive in patients with MRSA endocarditis. Fever was sustained and 13 bacteremia was prolonged (13). Howden et al. also reported resistance to rifampin 14 developing during vancomycin and rifampin combination therapy in three cases with 15 bacteremia (11). Emergence of resistance and prolonged bacteremia appeared to be risk 16 factors contributed to our patient's failure. Thus, in attempts to improve the bactericidal 17 capacity in patients with endocarditis, the regimens of combination therapy require 18 further evaluation. that associated with right-sided endocarditis (5). However, the usual dose for pediatric 10 patients is unknown and the efficacy for SARV should have further evaluation. 11
The emergence of SARV is becoming a challenge to the clinicians. Monitoring of 12 therapeutic level and adjusting the dosage of vancomycin in treating complicated cases is 13
warranted. An alternative regimen for SARV is needed for inoperable patients, and 14 linezolid could be considered a therapeutic option. With the increasing recognition of 15 SARV, further characterizations will help predict which isolates are most likely to 16 respond. 17 

